Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New industry association president sets priorities in Spain

This article was originally published in Scrip

Executive Summary

An alternative business model for the pharma industry, which is more in tune with the actual needs of health authorities and makes Spain more competitive, is among the priorities of Jesús Acebillo, the new president of the Spanish pharmaceutical industry associationFarmaindustria. He outlined his vision on strengthening the pharmaceutical industry earlier this week during his first public address. Mr Acebillo, president of the NovartisGroup in Spain, said that the industry should act responsibly to keep the national health system sustainable despite the current financial climate, and that better recognition of its innovation and research would continue to be a priority of the association. Mr Acebillo will serve a two-year term, replacing Antoni Esteve, now one of the association's six vice-presidents. The presidency of Farmaindustria rotates between representatives of local and multinational industry.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC030718

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel